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discharge, there was a signiﬁcant difference found between the
two groups for three muscle tests; chest press (p.023), leg
extension (p.007) and the isometric right knee ﬂexor test
(p.033). Though signiﬁcant values were not reached on all
tests, the differences between the pre- and post-scores of the
two groups for all physical capacity tests are between 16% and
35%, suggesting that the intervention was efﬁcient in prevent-
ing loss of and maintaining physical capacity.
Findings revealed that exercising patients during hospitalization
for allo-HSCT was feasible, safe and effective. In conclusion,
preventative and anticipatory interventions can minimize physical
and functional loss during hospitalization for allo-HSCT.
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CO-STIMULATORY MOLECULE EXPRESSION BY TRANSPLANTED DO-
NOR APC AND HOST CD4 T CELLS IS REQUIRED TO ELICIT RESISTANCE
AGAINST MHC-MATCHED HEMATOPOIETIC ALLOGRAFTS FOLLOWING
REDUCED INTENSITY CONDITIONING
Jones, M.1, Blazar, B.P.2, Zimmerman, Z.1, Levy, R.B.1 1University of
Miami Miller School of Medicine, Miami, FL; 2University of Minne-
sota, Minneapolis, MN.
Circumventing host resistance to hematopoietic progenitor
cell grafts is crucial for successful engraftment and the induc-
tion/maintenance of immune tolerance. We are studying the
regulation of pathways that lead to T cell resistance in recipients
transplanted with MHC-matched allogeneic BM (“MiHA-mis”)
following reduced intensity conditioning (RIC). To examine the
involvement of CD80/CD86 expression in this resistance,
CD80 and CD86 mabs were administered to B6 (wt) BMT
recipients. Donor BALB.B BM was not rejected in these recip-
ients. To investigate the requirement of CD80/86 expression on
recipient cells with respect to development of resistance, BM
was transplanted into wt or B6-CD80-/-86-/- mice. Donor chi-
merism in both recipients was transient indicating resistance
had been elicited against the donor BM. CD80-/-86-/- BM was
then transplanted into “MiHA-mis” recipients following RIC.
In contrast to wt BM grafts, transplantation of CD80-/-86-/- BM
resulted in sustained donor chimerism. Since “MiHA-mis” BM
transplants into CD4-/- recipients demonstrated CD4 cell func-
tion is critical for resistance in this model, we hypothesized that
host CD4 cell recognition of donor APC results in the upregu-
lation of CD80/CD86 co-stimulatory molecules. WT and
CD40L-/- mice were transplanted with BALB.B BM and as
predicted, wt recipients rejected the donor BM. In contrast,
CD40L-/- recipients exhibited stable chimerism. To examine
the requirement of CD40L on CD4 cells in the host, CD4-/-
mice were transplanted with BM together with CD4 cells from
wt or CD40L-/- mice. Recipients co-transplanted with wt CD4
cells rejected their grafts whereas recipients of CD4 cells from
CD40L-/- donors expressed donor cell chimerism and failed to
resist the MHC-matched BM allograft. We interpret the ﬁnd-
ings to demonstrate a requirement for host CD4 cells to recog-
nize donor MiHA and undergo alloantigen induced activation
resulting in CD40L induction of CD80/86 on donor APC.
These interactions subsequently result in host CD8 cell effector
activity inhibiting donor engraftment. Since recipients contain-
ing anti-donor speciﬁc CD8 memory cells were found to resist
MHC-matched HCT containing CD80-/-86-/- APC, these ﬁnd-
ings support the notion that direct recognition of donor APC is
crucial to elicit T cell mediated resistance to hematopoietic
engraftment in naive RIC MHC-matched allogeneic recipients.
Ex vivo mab treatment of donor BM is being examined as a
potential translational application.
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LOW RATES OF CHIMERISM OCCUR WHEN ALEMTUZUMAB IS ADDED
TO CONDITIONING THERAPY FOR NON-MYELOABLATIVE ALLOGENEIC
STEM CELL TRANSPLANTATION
Kasner, M.1, Loren, A.1, Stein, S.1, Goldstein, S.1, Luger, S.1,
Nasta, S.1, Perl, A.1, Schuster, S.1, Tsai, D.1, Andreadis, B.1,
Smith, J.1, Cole, S.1, Hinkle, J.1, Pillai, P.2, Emerson, S.1,
Stadtmauer, E.1, Porter, D.1 1University of Pennsylvania Cancer Cen-
ter, Philadelphia, PA; 2Pennsylvania Hospital, Philadelphia, PA.
Non-myeloablative allogeneic stem cell transplantation (NST)
aims to harness the graft-versus-tumor (GVT) effect while min-
imizing regimen-related toxicity, and relies on donor engraft-
ment to induce remission. The most appropriate GVHD pro-
phylaxis and preparative regimen in this setting remains poorly
deﬁned, though accumulating evidence suggests that full donor
chimerism is associated with maximal GVT effects and protec-
tion from relapse. Previously we found a high rate of donor
chimerism but a high incidence of severe GVHD using ﬂudara-
bine (ﬂu)/cyclophosphamide (Cy) conditioning and cyclospor-
ine (CSA)/mycophenolate moftil (MMF) as GVHD prophylaxis.
Subsequently, methotrexate (MTX) was substituted for MMF
and alemtuzumab (100 mg over 5 days, days -9 to -5) has been
added to our conditioning therapy in an attempt to both deplete
host antigen-presenting cells as well as infused donor T cells
and therefore minimize GVHD. Here we describe 55 patients
who received NST; 23 were conditioned with chemotherapy
alone and 33 were conditioned with alemtuzumab in addition to
ﬂu/Cy (n31) or ﬂu/melphalan (n2). All received CSA/MTX
post-transplant. The median age at NST was 50 years. Indica-
tions for transplant were Hodgkin’s disease (13), NHL (22),
MDS (7), CLL (5), myeloma (5) and 1 each with AML, breast
cancer, and and ovarian cancer. Most patients were heavily
pretreated and 62% had relapsed disease after prior autologous
SCT. There were no signiﬁcant differences between the groups
that did and did not receive alemtuzumab. Donor chimerism
was evaluated in all patients. 36% of patients conditioned with
alemtuzumabhad sustainable chimerism over 90%, and 42%
attained donor chimerism over 50%. This was signiﬁcantly
lower than in patients conditioned without alemtuzumab; 77%
and 82% had sustainable donor chimerism 90% and 50%
respectively (p0.005). There was no signiﬁcant difference in
median survival between patients treated with (12 mo) and
without (16 mo) alemtuzumab (p0.36). Relapse rates appeared
higher with alemtuzumab-containing regimens. Alemtuzumab
at this dose and schedule markedly decreased the incidence of
severe GVHD, but resulted in a higher incidence of graft-
rejection and hence lower rates of full and mixed donor chimer-
ism. Since full donor chimerism may be associated with freedom
from relapse, alternative conditioning regimens, and alternative
dosing and schedule of alemtuzumab administration (to deplete
host APC without in-vivo T cell depletion of the donor graft)
are being explored.
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OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION FOR PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKE-
MIA
Kennedy-Nasser, A.A.1, Arce, J.1, Leung, K.S.1, Gottschalk, S.1,
Bollard, C.M.1, Heslop, H.E.1, Brenner, M.K.1, Krance, R.A.1 1Center
for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s
Hospital, The Methodist Hospital, Houston, TX.
Although allogeneic hematopoietic stem cell transplantation
(HSCT) from an HLA-matched sibling offers curative therapy
for the small numbers of children who develop chronic myeloid
leukemia (CML), less than one third of patients have an appro-
priately matched sibling. Alternative donor transplantation has
had a higher procedure-associated risk, particularly for graft-
versus-host disease (GVHD). We have attempted to reduce
these risks by incorporating alemtuzumab (Campath 1H) into
the preparative regimens for alternative donor grafts. Between
1996 and 2006, 19 pediatric CML patients were transplanted
using either matched sibling (MSD; n  9) or alternative donor
(AD; 5 matched unrelated; 2 mismatched unrelated; 3 mis-
matched related). All recipients of MSD grafts were in chronic
phase at the time of transplant as were 6 of the AD recipients;
three of the AD recipients were in accelerated phase and 1 in
chronic phase presenting in lymphoid blast crisis at the time of
transplant. All recipients received myeloablative conditioning
consisting of cyclophosphamide 45mg/kg x 2, cytarabine arabi-
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noside 3g/m2 x 6 and TBI 1200-1400 cGy. In addition, AD
recipients received either ex vivo partial T-cell depletion or
Campath to achieve in vivo T-cell depletion in an effort to
reduce the risk of GVHD. Five AD patients died; 4 patients in
chronic phase and 1 patient in accelerated phase prior to trans-
plant. One patient died from recurrent disease and the other 4
from complications of therapy: 1 engraftment failure; 1 poor
engraftment and fungal disease; 1 cryptosporidium parasitemia;
and 1 pulmonary hemorrhage with viral infections. After trans-
plantation, 30% in each group (MSD and AD) required addi-
tional Gleevec or donor leukocyte infusions for BCR/ABL pos-
itivity. The Kaplan-Meier estimate of disease-free survival at 2
years was 78% for the entire cohort: 100% for the MSD group
and 56% for the AD group. Only 1 patient (AD recipient)
developed grade 3-4 acute GVHD and only 1 patient (AD
recipient) developed extensive, chronic GVHD. We conclude
that stem cell transplantation provides effective leukemia con-
trol and potential cure even for patients with advanced disease
who lack an MSD. Regimen-related mortality remains an im-
pediment to improved outcome for pediatric CML patients
receiving stem cells from unrelated or mismatched donors.
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ASSESSMENT OF ADENOVIRUS SUBGENERA PREVALENCE BY REAL-
TIME PCR IN IMMUNOCOMPROMISED PATIENTS
Duncan, K.1, Reddy, S.1, Vats, A.2, Kleiboeker, S.1 1ViraCor Labora-
tories, Lee’s Summit, MO; 2Children’s Hospital of Pittsburgh, Division
of Pediatric Nephrology, Pittsburgh, PA.
Background: Adenoviruses (Adv) are double-stranded DNA
viruses that can be classiﬁed by serotypes (1-51), which are
grouped into six subgenera (A-F). Within the different subgen-
era, viral characteristics vary in terms of host range, disease
type, and genetic composition. Real-time PCR has proven to be
a rapid, sensitive, and speciﬁc way to analyze the variable re-
gions of the Adv genome for subgenera determination. Using
this methodology, we determined the prevalence of Adv sub-
genera in a variety of Adv-positive clinical specimens collected
from immunocompromised patients.
Methods: Initially we utilized real time PCR TaqMan®
chemistry to quantify AdV DNA in clinical specimens using a
single pair of primers and a minor groove-binding probe (MGB)
designed to detect and quantitate all 51 Adv serotypes. From
specimens that were determined to be Adv-positive with this
assay, we randomly selected twenty-eight plasma, twenty-one
urine, and three fecal/rectal samples for Adv subgenera classi-
ﬁcation. Each specimen was analyzed by six individual Taq-
Man® assays (Watzinger et al., J. Clin. Microbiol 42:5189),
each designed to speciﬁcally detect all known serotypes within
each of the six subgenera.
Results: Plasma specimens tested with the pan-AdV assay had
viral loads ranging from 7.34101 – 5.73106 copies/ml. Urine
specimens had viral loads ranging from 1.24102 – 1.57107
copies/ml, and fecal/rectal samples had viral loads ranging from
9.04103 – 1.02.x107 0107 copies/ml. Subgenera determina-
tion for plasma demonstrated that 21% (6 samples) were Sub-
genus B, and 79% (22 samples) were Subgenus C. Results from
urine demonstrated that 81% (17 samples) were Subgenus B,
14% (3 samples) were Subgenus C, and 5% (1 sample) was
Subgenus D. Of the three fecal/rectal samples two were Subge-
nus D and one was Subgenus F. Using Fisher’s Exact Test, the
subgenera distribution among plasma and urine was determined
to be signiﬁcantly different (P0.0001; odds ratio20.78, 95%
CI: 4.526 to 95.38).
Conclusion: Results of this study demonstrate that the prev-
alence of AdV subgenera differ signiﬁcantly among specimen
types collected from immunocompromised patients. The pre-
dominant subgenus identiﬁed in urine was B while the predom-
inant subgenus identiﬁed in plasma was C. These results support
previous ﬁndings for prevalence in plasma and urine. Real-time
PCR technology provides an efﬁcient means to accurately diag-
nose Adenovirus infections and identiﬁcation of AdV subgenera.
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SUCCESSFUL HSCT AFTER MULTIVISCERAL TRANSPLANTATION
Kleiner, G.I.1, Gonzalez-Brito, M.1, Weppler, D.2, White, E.1,
Simon, N.3, David, A.2, Selvaggi, G.2, Kato, T.2, Shariatmadar, S.4,
Tzakis, A.2 1Department of Pediatrics, University of Miami, Miami,
FL; 2Division of Liver-GI Transplantation, University of Miami, Mi-
ami, FL; 3Jackson Memorial Hospital, Miami, FL; 4Department of
Pathology, University of Miami, Miami, FL.
Severe aplastic anemia following liver transplantation is a rare
phenomenon. We report the case of an eight year old girl who
developed SAA following multivisceral transplantation. The pa-
tient was diagnosed with intestinal pseudo obstruction and un-
derwent modiﬁed multivisceral transplant (stomach, pancreas,
spleen, small and large intestine) in December 2005. Post op-
erative course was uncomplicated but the patient developed SAA
six months later. There was no response to growth factors or
increased immunosuppression. The patient was housed in the
Pediatric ICU. Her brother was found to be HLA identical and
the patient underwent conditioning with Fludaribine 25mg/
m25, Cyclosphosphamide 50mg/kg x4, and ATG 30mg/kg x3.
She received 1.33  10e8 mnc/kg bone marrow. The patient
tolerated chemotherapy well. Post transplant course was com-
plicated by VRE treated with parenteral antibiotics and granu-
locyte transfusion support. The patient engrafted on day16.
FISH XY revealed 100% donor. We conclude that this reduced
intensity regimen may be effective in SAA cases following solid
organ transplantation.
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CORRELATION BETWEEN INFUSED MONONUCLEAR CELLS (MNC) AND
TRANSPLANT OUTCOME IN PEDIATRIC CORD BLOOD TRANSPLANTA-
TION (CBT). A STUDY OF 92 SINGLE CBT DONE AT CHILDREN’S
MEMORIAL HOSPITAL, CHICAGO, IL
Merchant, M.1, Olszewski, M.1, Huang, W.1, Duerst, R.1,2,
Jacobsohn, D.1,2, Kletzel, M.1,2 1Children’s Memorial Hospital, Chicago,
IL; 2Northwestern University Feinberg School of Medicine, Chicago, IL.
Objective:
To evaluate if there is a correlation between infused MNC cell
dose and transplant outcome in pediatric CBT.
Method:
Between January 1995 and February 2006, 125 CBT were carried
out at Children’s Memorial Hospital. 15 patients already had a
previous transplant and 18 patients required a subsequent trans-
plant after the initial CBT failed (primary or secondary graft failure
or relapse). Remaining 92 patients (43 female, 49 male) who un-
derwent a single CBT were evaluated in this study. 26 patients had
non-malignant conditions (SCID 7, HPCS 5, Wiskott-Aldrich
syndrome 3, 2 each of Aplastic anemia, Hurler’s syndrome and
Osteopetrosis, others 5) and 66 had malignancy (ALL 33, AML 21,
MDS 5, 2 each of Non-Hodgkin’s lymphoma and JMML, others
3). Disease status for malignancy at time of CBT was PR 7, CR1
24, CR2 28, CR 3/3 7. 69 patients received myeloablative con-
ditioning regimen (fTBI, VP-Cy, or Thiotepa. 4 patients received
Busulphan in place fTBI); 23 patients had reduced intensity con-
ditioning (Busulphan, Fludarabine, ATG). The median age at
transplant was 34.5 months (range 1 to 200), with median HLA
match of 4:6; ratio of cord sex was 53 female to 39 male. The
median MNC cell dose infused was 0.57  108/kg (range 0.08-
2.83). See table.
Results/Outcome:
Overall, 63 (68.5%) patients showed ANC engraftment (500
cells/	L), 58 (63.0%) showed PLT engraftment (20,000 cells/
	L) in a median of 24 (range 15- 60) and 44 (range 14- 105) days
respectively. 22 patients (23.9%) died within day 100 of CBT
from transplant related mortality. 13 patients (14.1%) had a re-
lapse. Overall 57 patients (62%) are event free at the present time
with an overall survival (OS) of 706 days.
Conclusions:
1. As the MNC cell dose increases, days required to achieve
engraftment (both ANC and PLT) decrease, showing these out-
come parameters are cell dose dependent.
2. Group 1 received the lowest cell dose (0.08- 0.29  108/kg)
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